A review of the preclinical development of zaleplon, a novel non- benzodiazepine hypnotic for the treatment of insomnia

CNS Drug Reviews

Volumn 3, Issue 3, 1997, Pages 207-224

  Beer, B ^a,b   Clody, D E ^a,c   Mangano, R ^a   Levner, M ^a   Mayer, P ^a   Barrett, J E ^a  

^a PFIZER INC   (United States)

^b DOV Pharmaceutical Inc   (United States)

^c Biometric Research Institute   (United States)

Author keywords

Hypnotics; Insomnia; Zaleplon

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE RECEPTOR; DIAZEPAM; DRUG METABOLITE; FLUMAZENIL; FLUNITRAZEPAM; FLURAZEPAM; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPNOTIC AGENT; RECEPTOR SUBTYPE; TERT BUTYLBICYCLOPHOSPHOROTHIOATE; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ALERTNESS; AMNESIA; BINDING SITE; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERANCE; EPILEPTIC STATE; HUMAN; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SEDATION;

EID: 0031412011     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1997.tb00324.x     Document Type: Review

References (27)

1. Beer B. Unpublished results, American Cyanamid Company Report.
2. A receptor subtypes: From pharmacology to molecular biology. FASEB J 1991;5:2916-2923.
3. Clody DE, Lippa AS, Beer B. Benzodiazepines and animal behavior: Preclinical procedures as predictors of anti-anxiety activity in man. In: Usdin E, Skolnick P, Tallman JF, Greenblatt D, Paul JM, eds. Pharmacology of benzodiazepine. London: Macmillan Press, Ltd., 1982:341-354.
4. Day IP, Clody DE, Monaghan M, Abel M, Dusza J, Beer B. Pharmacology of CL 284,846, a non-benzodiazepine sedative with reduced amnestic liability. Proc Soc Neurosci Anaheim, California, 1992.
5. Dementi WC. Rational basis for the use of sleeping pills. Int Pharmacopsychiat 1982;17:3-38.
6. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology (in press).
7. Hauri P. Primary Insomnia. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine, second ed. Philadelphia: WB Saunders, 1994:94-499.
8. Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin Pharmacokinetics 1988;4:1-12.
9. Linnoila M, Ellenwood E. Effects of benzodiazepines on performance of healthy volunteers and anxious and elderly patients. In: Usdin E, Skolnick P, Tallman JF, Greenblatt D, Paul JM, eds., Pharmacology of benzodiazepines. London: Macmillan Press Ltd., 1982:601-608.
10. Lippa AS, Meyerson LR, Beer B. Molecular substrates of anxiety: Clues from the heterogeneity of benzodiazepine receptors. Life Sci 1982;31:1409-1417.
11. A receptors: Pharmacology, behavioral roles and movement disorders. Neuroscientist 1996;2:15-23.
12. A/benzodiazepine receptor heterogeneity: Neurophysiological implications. Neuropharmacology 1995;34:245-254.
13. Macdonald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia (Suppl 4) 1994;35:S41-S50.
14. B receptors: Structure and function. Ann NY Acad Sci 1995;757:516-527.
15. National Commission on Sleep Disorders Research. Report of the National Commission on Sleep Disorders Research, U. S. Government Printing Office, Washington, D.C., 1992.
16. Nicholson AN. Hypnotics: clinical pharmacology and therapeutics. In: Kryger MH, Roth T, Dement WC, eds., Principles and practice of sleep medicine, second ed. Philadelphia: WB Saunders, 1994:355-363.
17. Rail TW. Hypnotics and Sedatives; ethanol. In: Goodman A, Gilman LD, eds. The pharmacological basis of therapeutics. New York: McMillan, 1990:345-382.
18. 35S]-butylbicyclophosphorothionate, a ligand that binds to the picrotoxin site. J Neurochem 1984;42:221-229.
19. Sanger DJ. Behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazol cue. Behav Pharmacol 1995;6:116-126.
20. Sanger DJ. The effects of new hypnotic drugs in rats trained to discriminate ethanol. Behav Pharmacol 1997;8:287-292.
21. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Pharmacol Biochem Behav 1994;18:355-372.
22. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs zaleplon and zolpidem. Eur J Pharmacol 1996;313:35-42.
23. A receptor subtypes. Pharmacol Rev 1995;47:181-234.
24. Squires RF, Benson DI, Braestrup C, et al. Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. Pharmacol Biochem Behav 1979;10:825-830.
25. Vanover KE, Barrett JE. Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846. Psychopharmacology 1994;115:289-296.
26. Vanover KE, Mangano RM, Barrett JE. CL 284,846, a novel sedative- hypnotic: Evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Devel Res 1994;33:39-45.
27. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971;21:1-7.